Serving Winnipeg's Jewish Community Submit to FacebookSubmit to Google BookmarksSubmit to TwitterSubmit to LinkedIn Youtube

By MYRON LOVE Former Winnipegger David Kideckel keeps going from strength to strength.

Last fall, the son of Howard Kideckel and Hope Springman was recruited by leading Bay Street investment bank Beacon Securities, and  charged with developing for the firm a new franchise focusing on healthcare and biotechnology.

Founded in 1988, BeaconSecurities is a full-service independent investment dealer, with a growing emphasis on mid-market institutional equities. The company serves clients worldwide across many different sectors.
“My position with Beacon Securities,” Kideckel says, “is Director, Institutional Equity Research - and Head of Healthcare & Biotechnology. This is a very exciting challenge. My mission is to identify the best up and coming companies in healthcare and biotechnology, both public and private companies that can benefit from our industry-leading approach to the capital markets.” We specialize in all aspects of capital markets including research, banking, sales and trading.

He notes that medical cannabis (marijuana) is a really hot area of research right now and that Israeli companies are among the world leaders in the field. Beacon is a leading provider for capital markets advisory for many of these companies.

You can certainly say that  Kideckel is at the top of his game. A graduate of the University of Winnipeg (University Gold Medallist, BSc and BA) and McMaster University (MSc, where he studied Albert Einstein’s brain), he has both a Ph.D in neuroscience and an MBA (2014) from the Institute of Medical Science at the University of Toronto and Rotman School of Management, respectively. He accomplished the latter with the elite Canadian Institutes of Health Research Science to Business Award, which is awarded to the most promising Ph.D’s in Canada to complete their MBAs. He has since been on the reviewing committee of this prestigious award where he helps to single out the most promising candidates for Canada’s future in innovation.
Only a select few in Canada were chosen to receive the award.

Another highlight of his academic career was being selected in 2009 as one of only three Canadians to take part in the Novartis International Biotechnology Leadership event at Novartis world headquarters in Cambridge, Massachusetts.
For the past 10 years – prior to joining Beacon Securities, also while working on his MBA – Kideckel had been working within pharmaceuticals, biotech and medical device companies, holding a number of senior and executive roles in international business development, marketing and medical affairs. His impressive resumé also includes roles as a business development executive with two biotechs run out of the MaRS Discovery District in Toronto, where he brokered deals in all parts of the world to advance Canadian biotech.

One of the latest projects Kideckel’s work achieved while at Beacon was a $35 million financing of a game changing technology to detect and treat prostate cancer – Profound Medical. He notes that this was an international deal completed with Beacon at the forefront of the financing and identification of top biotech originating out of Canada.
Kideckel sees a real need to strengthen Canada’s science and business and he strongly believes in giving back to his community through mentoring others .
 “I guess I’ve always had an entrepreneurial spirit,” he said.

Kideckel urges others who have studied science to also study business and gain business experience. He believes that merging the two disciplines holds the potential to make major contributions to health through science.
In an interview he gave to the Canadian Jewish News published on July 23, 2012, he was quoted as saying that the merger of science and business is “an untapped area with tons of potential”.
“The combined skill set allows people to work in areas like intellectual property, patent law, research, investment banking, innovation and the commercialization of scientific breakthroughs,” he added.

He also emphasized the importance of networking as much as possible. “It is important to really hear first hand from people what their experiences were,” he was quoted as saying. Kideckel still makes a point of meeting new people and building networks on an international scale.

And he further emphasized the importance of hands-on experience. “I believe in doing something and not just reading about it,” he was quoted as saying. Presently at Beacon Securities, Kideckel sees a plethora of companies coming to his firm to involve him and his team due to his unique background on Bay Street - namely his impressive hands on experience in big Pharma and biotech, which will allow the companies of tomorrow to gain an edge in his coverage of them from a very unique approach.

He notes that “we see companies target Beacon to involve his team as a result of the value-add he brings to the table. Having the educational qualifications coupled with direct industry experience is proving to be a highly sought after skill set, with very few individuals across Canada possessing it.

Add comment

Security code